Compare AbbVie Inc (ABBV) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? AbbVie Inc trades at $247.7 (market cap $441.94B), while Direxion Daily FTSE China Bull 3x Shares trades at $28.94. The key difference: AbbVie Inc pays a 2.77% dividend while Direxion Daily FTSE China Bull 3x Shares pays none, and AbbVie Inc is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| ABBV | YINN | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $263.58 | $56.62 |
52-Week Low | $197.38 | $21.45 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
YINN, a leveraged ETF tracking Chinese equities, trades at $29.20, down 9.6% in 24 hours amid bearish technical signals. Key support lies at $29, with resistance at $30–31. The fund's structure amplifies volatility, and financial ratios are unavailable due to its ETF nature. Recent news highlights China's AI investments and trade resilience, but geopolitical tensions and regulatory scrutiny persist.
Outlook remains cautious due to leverage risks and China's economic uncertainties. Opportunities exist if Hang Seng rebounds, but investors face elevated volatility from US-China frictions and ETF decay. Risks outweigh near-term catalysts, warranting careful position sizing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
